- Ofatumumab2011 | Faculty of Medicine in Hradec Králové
- Ofatumumab2021 | First Faculty of Medicine
- Ofatumumab in the treatment of multiple sclerosis2021 | Faculty of Medicine in Hradec Králové
- Ofatumumab and siponimod in the treatment of multiple sclerosis - case reports2022 | Faculty of Medicine in Hradec Králové
- Multiple sclerosis patient suitable for the treatment with ofatumumab2022 | Faculty of Medicine in Hradec Králové
- Ofatumumab - new and different monoclonal anti-CD20 antibody in the treatment of multiple sclerosis2021 | Second Faculty of Medicine
- Ofatumumab - a new high-efficacy treatment for relapsing forms of multiple sclerosis2021 | Faculty of Medicine in Hradec Králové
- Ofatumumab treatment of fludarabine and alemtuzumab refractory patients2012 | Faculty of Medicine in Hradec Králové
- Long-term efficacy and safety of ofatumumab in the treatment of multiple sclerosis2022 | Faculty of Medicine in Pilsen
- Ofatumumab - a highly effective therapy for relapsing-remitting multiple sclerosis available in the first line2022 | Faculty of Medicine in Hradec Králové
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. OMB112517Publication without faculty affiliation
- Research Report University Hospital for clinical assessment OMB113676Publication without faculty affiliation
- Report of University Hospital Hradec Králové to the clinical trial protocol No: OMB113676Publication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. GEN416Publication without faculty affiliation
- Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy2017 | Faculty of Medicine in Hradec Králové
- Monoclonal Antibodies in the Treatment of Chronic Lymphocytic Leukemia in 20152015 | First Faculty of Medicine
- Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study2015 | First Faculty of Medicine, Third Faculty of Medicine
- Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study2019 | Faculty of Medicine in Hradec Králové
- Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients2015 | Publication without faculty affiliation
- Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients2015 | Faculty of Medicine in Hradec Králové
- Capabilities to modulate inflammation in patients suffering from multiple sclerosis by biologics targeting CD20 molecule on mature B cells are expanding2020 | Faculty of Medicine in Hradec Králové
- Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study2022 | Faculty of Medicine in Hradec Králové
- The terapeutic Options for ""Slow- go"" Patients with Chronic Lymphocytic Leukemia2015 | Faculty of Medicine in Hradec Králové
- Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma2012 | Faculty of Medicine in Hradec Králové
- Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study2014 | First Faculty of Medicine
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia2010 | First Faculty of Medicine, Third Faculty of Medicine
- Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study2015 | Faculty of Medicine in Hradec Králové
- A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL2016 | Faculty of Medicine in Hradec Králové
- Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia2015 | Publication without faculty affiliation
- Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study2015 | Faculty of Medicine in Hradec Králové